Amifostine for Head and Neck Irradiation in Lymphoma
- Conditions
- LymphomaHodgkin's DiseaseNon-Hodgkin's Lymphoma
- Interventions
- Radiation: Radiation Therapy
- Registration Number
- NCT00136474
- Lead Sponsor
- Dana-Farber Cancer Institute
- Brief Summary
The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.
- Detailed Description
Patients will be randomized into one of two study groups. One study group will receive amifostine prior to daily radiation therapy and the other group will receive radiation therapy alone.
Amifostine will be administered 30-60 minutes prior to radiation treatment. Vital signs will be monitored 5 minutes and 15 minutes after amifostine injection as well as immediately following radiation treatment.
Patients will also complete a quality-of-life questionnaire on the first and last day of radiation treatment. Follow-up questionnaires will be done at follow-up visits 1 month, 3 months, 6 months, 12 months, 18 months and 24 months after completion of radiation therapy.
Patients will be removed from the study if they develop an allergic reaction to amifostine.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 75
- Patients must be 35 years or older
- Histologically confirmed Hodgkin's disease or non-Hodgkin's lymphoma receiving radiation therapy to the head and neck area.
- Involvement of one or more of the following sites: cervical node, supraclavicular node, pre-auricular node, submental node, any salivary glands, any parts of the oral cavity, or any parts of the oropharynx.
- Prior history of head and neck malignancies
- Prior radiation therapy to the head and neck region
- Patients with stage I Hodgkin's disease receiving radiation therapy alone
- Pregnant or lactating women
- Myocardial infarction within the 6 months of enrollment
- Clinically evident pulmonary insufficiency, except for patients with exertional dyspnea related to chest tumor itself.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 1 Radiation Therapy Amifostine plus radiation therapy Group 2 Radiation Therapy Radiation therapy alone Group 1 Amifostine Amifostine plus radiation therapy
- Primary Outcome Measures
Name Time Method To evaluate the effectiveness of amifostine in reducing acute and chronic radiation-induced side effects 2 years
- Secondary Outcome Measures
Name Time Method To determine the quality-of-life of patients receiving radiation therapy and amifostine to determine the safety of amifostine 2 years
Trial Locations
- Locations (2)
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States